MX2022011436A - Metodo de manejo de dismenorrea y dolor menstrual. - Google Patents

Metodo de manejo de dismenorrea y dolor menstrual.

Info

Publication number
MX2022011436A
MX2022011436A MX2022011436A MX2022011436A MX2022011436A MX 2022011436 A MX2022011436 A MX 2022011436A MX 2022011436 A MX2022011436 A MX 2022011436A MX 2022011436 A MX2022011436 A MX 2022011436A MX 2022011436 A MX2022011436 A MX 2022011436A
Authority
MX
Mexico
Prior art keywords
dysmenorrhea
management
estetrol
compounds
menstrual pain
Prior art date
Application number
MX2022011436A
Other languages
English (en)
Spanish (es)
Inventor
Maud Jost
Glwadys Rausin
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/076104 external-priority patent/WO2018065076A1/en
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of MX2022011436A publication Critical patent/MX2022011436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022011436A 2016-08-05 2019-01-30 Metodo de manejo de dismenorrea y dolor menstrual. MX2022011436A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16183025 2016-08-05
PCT/EP2016/076104 WO2018065076A1 (en) 2016-10-28 2016-10-28 Method for the management of dysmenorrhea and menstrual pain

Publications (1)

Publication Number Publication Date
MX2022011436A true MX2022011436A (es) 2022-11-14

Family

ID=56609757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011436A MX2022011436A (es) 2016-08-05 2019-01-30 Metodo de manejo de dismenorrea y dolor menstrual.

Country Status (12)

Country Link
US (2) US20190167700A1 (enExample)
JP (2) JP6557298B2 (enExample)
KR (1) KR102712911B1 (enExample)
AU (1) AU2022231672B2 (enExample)
BR (1) BR112019002203A2 (enExample)
CA (1) CA3178291A1 (enExample)
CO (1) CO2019000672A2 (enExample)
CR (1) CR20190112A (enExample)
MX (1) MX2022011436A (enExample)
PE (1) PE20190739A1 (enExample)
PH (1) PH12019500172B1 (enExample)
WO (1) WO2018024912A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
NZ737948A (en) 2015-06-18 2023-03-31 Estetra Sprl Orodispersible dosage unit containing an estetrol component
KR102662025B1 (ko) 2015-06-18 2024-05-02 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
AU2016425935B2 (en) * 2016-10-28 2023-01-19 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
MA51733A (fr) * 2018-02-07 2020-12-16 Estetra Sprl Composition contraceptive présentant des effets cardiovasculaires réduits
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CL2021001762A1 (es) * 2021-07-01 2022-01-21 Univ Pontificia Catolica Chile Uso del estetrol como tratamiento para la endometriosis
EP4134082A1 (en) * 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception
US12233074B2 (en) 2022-02-10 2025-02-25 Estetra Srl Contraceptive methods with improved pearl index
WO2024175486A1 (en) * 2023-02-23 2024-08-29 Estetra Srl Composition comprising estetrol and drospirenone for use in relieving and treating pain
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
CA1306950C (en) 1987-04-10 1992-09-01 Alec D. Keith Buccal administration of estrogens
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
JPH03237557A (ja) 1990-02-14 1991-10-23 Oki Electric Ind Co Ltd ニューラルネットワークシミュレータ及び計算機システム
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
AU2103495A (en) 1994-08-04 1996-03-04 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
JP2001526212A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
IL149424A (en) 1999-12-02 2007-05-15 Organon Nv Androgens are converted to methylene at positions 15,14
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
KR100913910B1 (ko) 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
PT1390040E (pt) 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
EP1390041B1 (en) 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
CA2448278C (en) 2001-05-23 2010-06-08 Christian Franz Holinka Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
EP1446128B1 (en) 2001-11-15 2006-12-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
EA007599B1 (ru) 2002-02-21 2006-12-29 Шеринг Акциенгезельшафт Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
CA2489270C (en) 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
AU2003274946A1 (en) 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
ATE382356T1 (de) 2002-07-12 2008-01-15 Pantarhei Bioscience Bv Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
HRP20050291A2 (en) 2002-08-28 2005-10-31 Zeev Shoham �ILRobert Casper et al. �CAGideon Kopernik �IL Estrogen replacement regimen
SI1556058T1 (sl) 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
WO2004041289A1 (en) 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
WO2004041839A2 (en) 2002-11-08 2004-05-21 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
DE602004002591T9 (de) 2003-05-22 2008-01-03 Pantarhei Bioscience B.V. Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
ES2933479T3 (es) 2003-09-29 2023-02-09 Novo Nordisk Healthcare Ag Estabilidad mejorada de formulaciones de progestágenos
PL1670440T3 (pl) 2003-09-29 2014-11-28 Novo Nordisk Healthcare Ag Preparaty HRT
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
ES2438734T3 (es) 2004-05-28 2014-01-20 Richter Gedeon Nyrt. Anticonceptivo que contiene ácido fólico
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
UA88943C2 (ru) 2005-02-03 2009-12-10 Нікомед Фарма Ас Быстрый способ влажного гранулирования для получения композиций, которые содержат кальций
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN102796160A (zh) 2005-05-26 2012-11-28 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
JP2008545012A (ja) 2005-06-29 2008-12-11 ワイス 結合型エストロゲンおよびバゼドキシフェンの医薬処方
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
CN101378762A (zh) 2006-01-09 2009-03-04 潘塔希生物科学股份有限公司 一种治疗急性血管疾病的方法
CA2636638C (en) 2006-01-09 2014-02-18 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
WO2007106264A2 (en) 2006-03-02 2007-09-20 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
SG174785A1 (en) 2006-06-08 2011-10-28 Warner Chilcott Co Llc Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
BRPI0713999A2 (pt) 2006-07-06 2012-11-20 Bayer Schering Pharma Ag produÇço farmacÊutica para contracepÇço e para reduÇço do risco de malformaÇÕes congÊnitas
TW200831139A (en) 2006-11-29 2008-08-01 Wyeth Corp Estrogen/SERM and estrogen/progestin bi-layer tablets
CA2674776A1 (en) 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
DE602008001783D1 (de) 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
MX2009007254A (es) 2007-01-12 2009-08-12 Wyeth Corp Composiciones de tableta en tableta.
WO2008156365A1 (en) 2007-06-21 2008-12-24 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
ES2376793T3 (es) 2007-07-19 2012-03-16 Pantarhei Bioscience B.V. Tratamiento o prevención de trastornos hipertensivos del embarazo o retraso del crecimiento fetal
WO2010033832A2 (en) 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
EP3031451B1 (en) 2009-01-26 2018-03-07 Shin-Etsu Chemical Co., Ltd Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
NZ597239A (en) 2009-06-23 2013-07-26 Bayer Pharma AG Pharmaceutical composition for emergency contraception
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
JP5945267B2 (ja) 2010-04-12 2016-07-05 ユニヴェルシテ クロード ベルナール リヨン １ 有機ケイ素ゾルの急速縮合によって得られるハイブリッド材料の製造方法
KR20130097073A (ko) 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
CN107028900A (zh) 2010-12-02 2017-08-11 艾戴尔医药公司 快速分散颗粒、口腔崩解片以及方法
JP6425540B2 (ja) 2011-06-01 2018-11-21 エステトラ エス．ペ．エール．エル． エステトロール中間体を製造するための方法
CL2013003435A1 (es) 2011-06-01 2014-08-01 Estetra Sprl Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol.
EP2714712B1 (en) 2011-06-01 2016-08-24 Estetra S.P.R.L. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US10179107B2 (en) 2011-07-19 2019-01-15 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (DHEA)
SMT201700310T1 (it) 2011-08-11 2017-07-18 Estetra Sprl Uso dell'esterolo come contraccettivo di emergenza
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition
SI2764008T1 (sl) 2011-10-07 2016-10-28 Estetra S.P.R.L. Postopek za pripravo estetrola
EP2790688B1 (en) 2011-12-13 2019-11-20 Arstat, Inc. A multiphasic contraceptive regimen for an oral formulation of progestin and estrogen
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
US20140341326A1 (en) 2013-05-20 2014-11-20 Qualcomm Incorporated Channel estimation with discontinuous pilot signals
MX2015016038A (es) 2013-05-21 2016-03-21 Predictive Therapheutics Llc Agente terapéutico y método de uso.
JP6254289B2 (ja) 2013-09-18 2017-12-27 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． エステトロールの製造プロセス
US12274276B2 (en) 2013-10-03 2025-04-15 Altria Client Services Llc Dissolvable-chewable tablet
MA39105B1 (fr) 2013-12-12 2018-05-31 Donesta Bioscience B V Unité de dosage solide se désintégrant par voie orale contenant un constituant estétrol
WO2016023009A1 (en) 2014-08-07 2016-02-11 Wake Forest University Health Sciences Compositions and methods for clearing a biological sample
ES2957543T3 (es) 2014-09-29 2024-01-22 Univ California Composiciones y métodos para mantener la función cognitiva
BR112017024783A2 (pt) 2015-05-18 2018-08-07 Agile Therapeutics Inc composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais
NZ737948A (en) 2015-06-18 2023-03-31 Estetra Sprl Orodispersible dosage unit containing an estetrol component
KR102662025B1 (ko) 2015-06-18 2024-05-02 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
LT3313408T (lt) 2015-06-23 2024-03-12 Laboratorios Leon Farma Sa Kontraceptikas drospirenono pagrindu, skirtas pacientėms, turinčioms antsvorio
AU2016425935B2 (en) 2016-10-28 2023-01-19 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CA3178291A1 (en) * 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
MA51733A (fr) 2018-02-07 2020-12-16 Estetra Sprl Composition contraceptive présentant des effets cardiovasculaires réduits
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
JP2019163318A (ja) 2019-09-26
AU2022231672B2 (en) 2024-03-07
JP2018165263A (ja) 2018-10-25
PE20190739A1 (es) 2019-05-23
US20190167700A1 (en) 2019-06-06
CR20190112A (es) 2019-06-25
JP7177313B2 (ja) 2022-11-24
KR102712911B1 (ko) 2024-10-04
US11896602B2 (en) 2024-02-13
AU2022231672A1 (en) 2022-10-06
US20230041304A1 (en) 2023-02-09
PH12019500172B1 (en) 2024-02-28
JP6557298B2 (ja) 2019-08-07
CO2019000672A2 (es) 2019-04-30
PH12019500172A1 (en) 2019-07-29
KR20220144885A (ko) 2022-10-27
WO2018024912A1 (en) 2018-02-08
CA3178291A1 (en) 2018-04-12
BR112019002203A2 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
MX2022011436A (es) Metodo de manejo de dismenorrea y dolor menstrual.
MY205032A (en) Method for the management of dysmenorrhea and menstrual pain
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2015073587A3 (en) Synthetic membrane-receiver complexes
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
AU2016261707A8 (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
PH12019502174A1 (en) Modulators of pcsk9 expression
NZ756936A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2025006615A (es) Metodos para alterar la composicion corporal
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018003087A (es) Metodo para influir en el tacto.
MX2022015456A (es) Composiciones de maca y metodos de uso.
MX2018004120A (es) Composiciones fraguables con diversos tiempos de fraguado.
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2016008821A (es) Composiciones lacteas fermentadas coladas y aireadas.
MX2019001298A (es) Metodo de manejo de dismenorrea y dolor menstrual.
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
MX2018006882A (es) Composiciones farmacéuticas de estradiol insertadas por vía vaginal y métodos.
GB2528406A (en) Prebiotic composition and method of its use
HUE064011T2 (hu) Teljesítménynövelõ adalékanyag üzemanyag-összetételhez és a felhasználásának módja
PL3710565T3 (pl) Kompozycje dodatku do paliwa i sposób ich stosowania